Form 4: Stoke Therapeutics Director Julie Smith Granted Stock Options

Director Julie Smith of Stoke Therapeutics, Inc. was granted stock options on June 5, 2024, according to a Form 4 filing with the SEC.

Summary

• Julie Smith, a director of Stoke Therapeutics, Inc., was granted stock options on June 5, 2024.
• The options allow her to purchase 7,639 shares of common stock at an exercise price of $16.41 per share.
• The options vest on the earlier of June 5, 2025, or the date of the company's next annual meeting, contingent upon her continued service.
• A Limited Power of Attorney was executed, appointing Edward M. Kaye, Jonathan Allan, and Thomas Leggett as Attorneys-in-Fact to handle SEC filings on Smith's behalf.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to directors, which is generally viewed positively as it aligns interests with shareholders. There are no indications of negative news or concerns.

Positives

• The granting of stock options to a director aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies such as Biogen, Vertex Pharmaceuticals, and Alnylam Pharmaceuticals also utilize stock options as part of their director compensation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability.

Key Dates